BR9807096A - Compound, processes for the treatment of diabetes, obesity in a mammal, to reduce levels of triglycerides and cholesterol levels or to raise levels of high density lipoproteins, to decrease motility of the intestine, to reduce neurogenic inflammation of the airways and depression and to treat gastrointestinal disorders, and, compositions for the treatment of the above and pharmaceutical disorders - Google Patents
Compound, processes for the treatment of diabetes, obesity in a mammal, to reduce levels of triglycerides and cholesterol levels or to raise levels of high density lipoproteins, to decrease motility of the intestine, to reduce neurogenic inflammation of the airways and depression and to treat gastrointestinal disorders, and, compositions for the treatment of the above and pharmaceutical disordersInfo
- Publication number
- BR9807096A BR9807096A BR9807096-7A BR9807096A BR9807096A BR 9807096 A BR9807096 A BR 9807096A BR 9807096 A BR9807096 A BR 9807096A BR 9807096 A BR9807096 A BR 9807096A
- Authority
- BR
- Brazil
- Prior art keywords
- levels
- reduce
- treatment
- disorders
- compounds
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 8
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 102000015779 HDL Lipoproteins Human genes 0.000 title abstract 4
- 108010010234 HDL Lipoproteins Proteins 0.000 title abstract 4
- 208000008589 Obesity Diseases 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 208000035475 disorder Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 235000020824 obesity Nutrition 0.000 title abstract 3
- 208000007920 Neurogenic Inflammation Diseases 0.000 title abstract 2
- 210000000936 intestine Anatomy 0.000 title abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 title 1
- 241000124008 Mammalia Species 0.000 title 1
- 230000004899 motility Effects 0.000 title 1
- 150000003626 triacylglycerols Chemical class 0.000 title 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 2
- 108060003345 Adrenergic Receptor Proteins 0.000 abstract 1
- 102000017910 Adrenergic receptor Human genes 0.000 abstract 1
- -1 Thiazole-substituted benzenesulfonamides Chemical class 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002118 epoxides Chemical class 0.000 abstract 1
- 230000010243 gut motility Effects 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 230000008991 intestinal motility Effects 0.000 abstract 1
- 230000004130 lipolysis Effects 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMPOSTO, PROCESSOS PARA O TRATAMENTO DO DIABETES, DA OBESIDADE EM UM MAMìFERO, PARA REDUZIR NìVEIS DE TRIGLICERìDEOS E NìVEIS DE COLESTEROL OU ELEVAR NìVEIS DE LIPOPROTEìNA DE ALTA DENSIDADE, PARA DIMINUIR A MOTILIDADE DO INTESTINO, PARA REDUZIR INFLAMAçãO NEUROGêNICA DAS VIAS AéREAS E A DEPRESSãO E PARA TRATAR DISTúRBIOS GASTRINTESTINAIS, E, COMPOSIçõES PARA O TRATAMENTO DOS DISTúRBIOS ACIMA E FARMACêUTICA". Benzenosulfonamidas substituídas por tiazol constituem agonistas de receptor adrenérgico <225>3 com muito pouca atividade de receptor adrenérgico <225>1 e <225>2 e, como tal, os compostos são capazes de aumentar a lipólise e o dispêndio de energia nas células. Os compostos também podem ser usados para reduzir os níveis de triglicerídeos e os níveis de colesterol, ou elevar os níveis de lipoproteína de alta densidade ou diminuir a motilidade do intestino. Adicionalmente, os compostos podem ser usados para reduzir inflamação neurogênica ou como agentes antidepressores. Os compostos são preparados acoplando-se uma aminoalquilfenil-sulfonamida com um epóxido apropriadamente substituído. Também se descreve composições e processos para o uso dos compostos no tratamento do diabetes e da obesidade e para reduzir os níveis de triglicerídeos e os níveis de colesterol ou para elevar os níveis de lipoproteína de alta densidade ou para reduzir a motilidade do intestino."COMPOUND, PROCESSES FOR THE TREATMENT OF DIABETES, OBESITY IN A MAMMALIAN, TO REDUCE TRIGLYCERIDAL LEVELS AND LEVELS OF CHOLESTEROL OR ELEVATE LEVELS OF HIGH DENSITY LIPOPROTEIN, TO REDUCE THE INTESTINAL TRAINING AND REDUCING THE INTESTININE OF THE INTESTININE OF THE INTESTINE DEPRESSION AND TO TREAT GASTRINTESTINAL DISORDERS, AND, COMPOSITIONS FOR THE TREATMENT OF ABOVE AND PHARMACEUTICAL DISORDERS ". Thiazole-substituted benzenesulfonamides constitute <225> 3 adrenergic receptor agonists with very little <225> 1 and <225> 2 adrenergic receptor activity and, as such, the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds can also be used to reduce triglyceride levels and cholesterol levels, or to raise high-density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduce neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl sulfonamide with an appropriately substituted epoxide. Also described are compositions and processes for the use of the compounds in the treatment of diabetes and obesity and to reduce triglyceride levels and cholesterol levels or to raise high density lipoprotein levels or to reduce intestinal motility.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3676097P | 1997-01-28 | 1997-01-28 | |
| GBGB9705041.3A GB9705041D0 (en) | 1997-03-12 | 1997-03-12 | Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity |
| PCT/US1998/001317 WO1998032753A1 (en) | 1997-01-28 | 1998-01-23 | THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9807096A true BR9807096A (en) | 2000-04-18 |
Family
ID=26311166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9807096-7A BR9807096A (en) | 1997-01-28 | 1998-01-23 | Compound, processes for the treatment of diabetes, obesity in a mammal, to reduce levels of triglycerides and cholesterol levels or to raise levels of high density lipoproteins, to decrease motility of the intestine, to reduce neurogenic inflammation of the airways and depression and to treat gastrointestinal disorders, and, compositions for the treatment of the above and pharmaceutical disorders |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0968209A1 (en) |
| JP (1) | JP2001509166A (en) |
| KR (1) | KR20000070568A (en) |
| CN (1) | CN1251099A (en) |
| AR (1) | AR011092A1 (en) |
| AU (1) | AU728812B2 (en) |
| BG (1) | BG103686A (en) |
| BR (1) | BR9807096A (en) |
| CA (1) | CA2278739A1 (en) |
| EA (1) | EA199900692A1 (en) |
| EE (1) | EE9900328A (en) |
| HR (1) | HRP980044A2 (en) |
| HU (1) | HUP0002053A3 (en) |
| ID (1) | ID22273A (en) |
| IL (1) | IL131130A0 (en) |
| IS (1) | IS5131A (en) |
| NO (1) | NO993646L (en) |
| PE (1) | PE52299A1 (en) |
| PL (1) | PL334833A1 (en) |
| SK (1) | SK100099A3 (en) |
| TR (1) | TR199902442T2 (en) |
| WO (1) | WO1998032753A1 (en) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19824175A1 (en) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino azole compounds |
| DK1741446T3 (en) | 2000-01-21 | 2008-06-02 | Novartis Pharma Ag | Combinations containing dipeptidyl peptidase IV inhibitors and antidiabetic agents |
| US20030018061A1 (en) * | 2000-01-28 | 2003-01-23 | Kohei Ogawa | Novel remedies with the use of beta 3 agonist |
| PT1138685E (en) * | 2000-03-31 | 2004-08-31 | Pfizer Prod Inc | PROCESS FOR THE PREPARATION OF REPLACED PYRIDINES |
| HRP20030018A2 (en) * | 2000-07-13 | 2003-04-30 | Lilly Co Eli | Beta3 adrenergic agonists |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
| US6498170B2 (en) | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
| US6369232B1 (en) * | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
| CA2421594A1 (en) | 2000-11-10 | 2002-05-16 | John Arnold Werner | 3-substituted oxindole beta 3 agonists |
| CA2431171A1 (en) | 2000-12-08 | 2002-06-13 | Takeda Chemical Industries, Ltd. | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
| AR035605A1 (en) | 2000-12-11 | 2004-06-16 | Bayer Corp | DERIVATIVES OF AMINOMETIL CHROMANO DI-SUBSTITUTES, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3-ADRENE-RECEPTORS AGONISTS |
| AR035858A1 (en) | 2001-04-23 | 2004-07-21 | Bayer Corp | CHROME DERIVATIVES 2,6-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS, USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3 ADRENORRECEPTING AGONISTS |
| ATE316088T1 (en) * | 2001-06-22 | 2006-02-15 | Merck & Co Inc | TYROSINE KINASE INHIBITORS |
| DE60215028T2 (en) | 2001-08-14 | 2007-03-15 | Eli Lilly And Co., Indianapolis | INDOL DERIVATIVES AS BETA-3-ADRENERGE AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES |
| WO2003016276A2 (en) | 2001-08-14 | 2003-02-27 | Eli Lilly And Company | 3-substituted oxindole beta-3 agonists |
| US20050014805A1 (en) * | 2001-10-12 | 2005-01-20 | Chenzhi Zhang | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
| AU2002347982A1 (en) | 2001-11-20 | 2003-06-10 | Eli Lilly And Company | 3-SUBSTITUTED OXINDOLE Beta3 AGONISTS |
| ES2299618T3 (en) | 2001-11-20 | 2008-06-01 | Eli Lilly And Company | BETA-3-ADRENERGIC AGONISTS. |
| JP2005520805A (en) | 2002-01-11 | 2005-07-14 | イーライ・リリー・アンド・カンパニー | 2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists |
| US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS |
| WO2006132196A1 (en) * | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | NOVEL PHARMACEUTICAL COMPRISING β3 AGONIST |
| CN101309689B (en) | 2005-09-14 | 2012-10-10 | 武田药品工业株式会社 | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| CN101277960A (en) | 2005-09-29 | 2008-10-01 | 默克公司 | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| WO2007044296A2 (en) * | 2005-10-04 | 2007-04-19 | Merck & Co., Inc. | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| JP5319518B2 (en) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | Indoledione derivative |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| US8802695B2 (en) | 2010-02-03 | 2014-08-12 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| BR112013021236B1 (en) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | benzimidazole derivative compound, and, composition |
| US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| ES2394349B1 (en) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Use of selective beta-3 adrenergic receptor agonists for the treatment of pulmonary hypertension |
| US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
| MX2015010935A (en) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Antidiabetic bicyclic compounds. |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| AU2014274812B2 (en) | 2013-06-05 | 2018-09-27 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201903832D0 (en) | 2019-03-20 | 2019-05-01 | Atrogi Ab | New compounds and methods |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0091749A3 (en) * | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) * | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
-
1998
- 1998-01-23 CA CA002278739A patent/CA2278739A1/en not_active Abandoned
- 1998-01-23 EP EP98903677A patent/EP0968209A1/en not_active Withdrawn
- 1998-01-23 TR TR1999/02442T patent/TR199902442T2/en unknown
- 1998-01-23 EE EEP199900328A patent/EE9900328A/en unknown
- 1998-01-23 WO PCT/US1998/001317 patent/WO1998032753A1/en not_active Ceased
- 1998-01-23 KR KR1019997006814A patent/KR20000070568A/en not_active Withdrawn
- 1998-01-23 JP JP53214898A patent/JP2001509166A/en active Pending
- 1998-01-23 SK SK1000-99A patent/SK100099A3/en unknown
- 1998-01-23 AU AU60384/98A patent/AU728812B2/en not_active Ceased
- 1998-01-23 ID IDW990755A patent/ID22273A/en unknown
- 1998-01-23 BR BR9807096-7A patent/BR9807096A/en not_active IP Right Cessation
- 1998-01-23 HU HU0002053A patent/HUP0002053A3/en unknown
- 1998-01-23 CN CN98803585A patent/CN1251099A/en active Pending
- 1998-01-23 IL IL13113098A patent/IL131130A0/en unknown
- 1998-01-23 EA EA199900692A patent/EA199900692A1/en unknown
- 1998-01-23 PL PL98334833A patent/PL334833A1/en unknown
- 1998-01-27 AR ARP980100357A patent/AR011092A1/en unknown
- 1998-01-28 HR HR9705041.3A patent/HRP980044A2/en not_active Application Discontinuation
- 1998-01-28 PE PE1998000064A patent/PE52299A1/en not_active Application Discontinuation
-
1999
- 1999-07-23 IS IS5131A patent/IS5131A/en unknown
- 1999-07-27 NO NO993646A patent/NO993646L/en not_active Application Discontinuation
- 1999-08-24 BG BG103686A patent/BG103686A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL131130A0 (en) | 2001-01-28 |
| EE9900328A (en) | 2000-02-15 |
| IS5131A (en) | 1999-07-23 |
| AU728812B2 (en) | 2001-01-18 |
| TR199902442T2 (en) | 2000-07-21 |
| PE52299A1 (en) | 1999-05-26 |
| SK100099A3 (en) | 2000-05-16 |
| AU6038498A (en) | 1998-08-18 |
| HUP0002053A3 (en) | 2001-09-28 |
| JP2001509166A (en) | 2001-07-10 |
| BG103686A (en) | 2000-06-30 |
| HUP0002053A2 (en) | 2001-08-28 |
| WO1998032753A1 (en) | 1998-07-30 |
| HRP980044A2 (en) | 1998-10-31 |
| CA2278739A1 (en) | 1998-07-30 |
| NO993646D0 (en) | 1999-07-27 |
| EA199900692A1 (en) | 2000-02-28 |
| PL334833A1 (en) | 2000-03-27 |
| AR011092A1 (en) | 2000-08-02 |
| ID22273A (en) | 1999-09-23 |
| NO993646L (en) | 1999-09-27 |
| CN1251099A (en) | 2000-04-19 |
| EP0968209A1 (en) | 2000-01-05 |
| KR20000070568A (en) | 2000-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9807096A (en) | Compound, processes for the treatment of diabetes, obesity in a mammal, to reduce levels of triglycerides and cholesterol levels or to raise levels of high density lipoproteins, to decrease motility of the intestine, to reduce neurogenic inflammation of the airways and depression and to treat gastrointestinal disorders, and, compositions for the treatment of the above and pharmaceutical disorders | |
| Zhu et al. | Mesenchymal stem cells in osteoarthritis therapy: a review | |
| Bunker | Frozen shoulder: unravelling the enigma | |
| Wang et al. | Regulation effects of melatonin on bone marrow mesenchymal stem cell differentiation | |
| Duthon et al. | Anatomy of the anterior cruciate ligament | |
| Huegel et al. | Rotator cuff biology and biomechanics: a review of normal and pathological conditions | |
| Garg et al. | Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury | |
| BR0112409A (en) | Adrenergic beta3 agonists | |
| Buckwalter et al. | Loading of healing bone, fibrous tissue, and muscle: implications for orthopaedic practice | |
| Ueblacker et al. | Treatment of muscle injuries in football | |
| AU5498694A (en) | Substituted phenyl sulfonamides as selective Beta3 agonists for the treatment of diabetes and obesity | |
| BR0206985A (en) | Modified Antibodies and Methods of Use | |
| Song et al. | Circadian rhythm‐regulated ADSC‐derived sEVs and a triphasic microneedle delivery system to enhance tendon‐to‐bone healing | |
| Meyer et al. | Muscle progenitor cell regenerative capacity in the torn rotator cuff | |
| Voorburg et al. | Vasculitis due to gemcitabine | |
| Lai et al. | Metabolic syndrome and tendon disease: a comprehensive review | |
| Guo et al. | Ginsenoside Rg1/ADSCs supplemented with hyaluronic acid as the matrix improves rabbit temporomandibular joint osteoarthrosis | |
| Bunker | (ii) Frozen shoulder | |
| Liu et al. | Programmed BRD9 Degradation and Hedgehog Signaling Activation via Silk‐Based Core‐Shell Microneedles Promote Diabetic Wound Healing | |
| BR112022016990A2 (en) | RECOMBINANT A ALPHA-GALACTOSIDASES AND/OR BIOLOGICALLY ACTIVE RECOMBINANT ALPHA-GALACTOSIDASE A FRAGMENT, COMPOSITION, RECOMBINANT POLYNUCLEOTIDE SEQUENCE, EXPRESSION VECTOR, HOST CELL, METHODS FOR PRODUCING AN ALPHA-GALACTOSIDASE A VARIANT AND TO TREAT AND/OR PREVENT SYMPTOMS OF FABRY'S DISEASE IN AN INDIVIDUAL, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FABRY'S DISEASE, PHARMACEUTICAL COMPOSITION, AND, USE OF THE COMPOSITIONS | |
| Warditiani et al. | Molecular pharmacology study of andrographolide extracted from andrographis paniculata on atherosclerosis preventive effect | |
| Wheaton et al. | The Ligament Injury-Osteoarthritis Connection: The Role of Prolotherapy in Ligament Repair | |
| Zhang et al. | Preliminary investigation on the effect of extracorporeal shock wave combined with traction on joint contracture based on PTEN‐PI3K/AKT pathway | |
| Ma et al. | Is there a duration-characteristic relationship for trypsin exposure on tendon? A study on anterior cruciate ligament reconstruction in a rabbit model | |
| Ao et al. | Sport medicine among the past three decades in China |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A,7A,8A E 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1887 DE 06/03/2007. |